Global Tumor Biomarker Test Kits Market: Growth Drivers, Segment Analysis & Future Outlook (2023–2030)

 

The Global Tumor Biomarker Test Kits Market, valued at USD 13.1 billion in 2022, is projected to reach USD 29.76 billion by 2030, growing at an impressive CAGR of 10.8% during the forecast period (2023–2030). Tumor biomarker test kits play a crucial role in the early detection, monitoring, and personalized treatment of cancers, making them an indispensable component of modern healthcare systems.

Understanding Tumor Biomarker Test Kits

Biomarkers are biological indicators that reveal the presence or progression of disease. Tumor biomarker test kits detect changes in:

• Genes
• Proteins
• Other biological molecules

These kits enable early detection of cancer, monitoring of disease progression, and evaluation of treatment efficiency. When paired with targeted therapies, these tests are often referred to as companion diagnostics, forming a key pillar of precision medicine.

Download Sample

Market Growth Drivers

1. Rising Global Cancer Prevalence

The increasing incidence of cancer worldwide remains the primary driver of market expansion. Higher detection rates and improved awareness have further pushed the demand for reliable, accurate biomarker testing.

2. Technological Advancements

Innovations in genetic sequencing, proteomics, metabolomics, and imaging have significantly transformed biomarker testing, making it more precise and accessible.

3. Increasing Preference for Non-Invasive Testing

Patients and healthcare providers favor tumor biomarker kits due to their non-invasive, cost-effective, and highly efficient nature, compared to traditional biopsy-based methods.

4. Growing R&D Investments

Pharmaceutical companies are heavily investing in R&D to develop advanced diagnostic kits, contributing significantly to the overall market growth.

Enquire Before Buying

Market Segmentation Analysis

1. By Tumor Detection

• Lung
• Breast
• Ovarian
• Liver
• Stomach
• Prostate
• Others

Lung Cancer Leads the Market

Lung cancer remains the second leading cause of cancer-related deaths globally, accounting for over 13% of all new cases in 2022. Exposure to tobacco, radiation, asbestos, and air pollution are major risk factors. This high prevalence has resulted in lung cancer biomarker test kits dominating this segment, with strong growth expected through 2030.

Breast cancer biomarker kits also showed strong performance in 2022 and are projected to witness steady growth in the upcoming years.

 

2. By Type

• Protein
• Genetic
• Others

Protein Biomarkers Remain Dominant

The Protein segment led the market in 2022 and is expected to maintain dominance. Protein biomarkers are widely used for their accuracy, stability, and ability to detect a wide spectrum of tumors. Increasing reliance on protein expression analysis in cancer research further boosts this segment.

 

3. By Application

• Diagnostic Laboratories
• Research Institutes
• Pharmaceutical Companies

Pharmaceutical Companies Hold the Largest Share

With a commanding 45% market share in 2022, pharmaceutical companies remain the top contributors, driven by their investment in developing targeted therapies and personalized treatment solutions.

Diagnostic laboratories and research institutes are also driving significant growth thanks to increased funding for clinical research and demand for advanced testing technologies.

 

4. By Technology

• Immunoassay
• Imaging
• Omics
• Others

Omics Technology Leads the Market

The Omics segment—including genomics, proteomics, and metabolomics—dominated in 2022 due to its effectiveness in early tumor detection and precision diagnostics. Demand for Immunoassay-based tests is also rising as clinical trials increasingly incorporate this technology for biomarker analysis.

Buy Now

Key Market Players

Major companies contributing to market growth include:

• Prestige Biopharma
• BioAgilytix Labs
• Eurofins Scientific
• SGS SA
• OncoDEEP
• ICON Plc
• IQVIA
• Syneos Health
• Nonagen Bioscience
• Intertek Group

These players are focused on expanding their testing capabilities, enhancing diagnostic accuracy, and advancing personalized medicine through strategic collaborations and investments.